GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Other Long-Term Liabilities

Boundless Bio (Boundless Bio) Other Long-Term Liabilities : $247.62 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Other Long-Term Liabilities?

Boundless Bio's other long-term liabilities for the quarter that ended in Mar. 2024 was $247.62 Mil.

Boundless Bio's quarterly other long-term liabilities stayed the same from Sep. 2023 ($247.62 Mil) to Dec. 2023 ($247.62 Mil) but then increased from Dec. 2023 ($247.62 Mil) to Mar. 2024 ($247.62 Mil).

Boundless Bio's annual other long-term liabilities declined from Dec. 2021 ($148.04 Mil) to Dec. 2022 ($147.95 Mil) but then increased from Dec. 2022 ($147.95 Mil) to Dec. 2023 ($247.62 Mil).

Boundless Bio Other Long-Term Liabilities Historical Data

The historical data trend for Boundless Bio's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Other Long-Term Liabilities Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Other Long-Term Liabilities
- - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only - - - - -

Boundless Bio Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Boundless Bio Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio (Boundless Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Other Long-Term Liabilities
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
https://www.boundlessbio.com
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Boundless Bio (Boundless Bio) Headlines

From GuruFocus

Boundless Bio Announces Pricing of Initial Public Offering

By Business Wire • 03-27-2024